Plozasiran EU Approval: Dosing Convenience Without Efficacy Superiority Tests Payer Tolerance at 80% Cost Premium

Arrowhead's Redemplo Gains EU Authorization for FCS

Arrowhead Pharmaceuticals recently announced that the European Commission (EC) has granted marketing authorisation for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor, for the treatment of adults with familial chylomicronemia syndrome (FCS) in the EU. This follows its prior approval in the US. The approval is supported by Phase III PALISADE study data, which demonstrated substantial reductions in triglyceride levels (80% with 25mg dose) and an 83% reduction in the incidence of acute pancreatitis. This authorization addresses a significant unmet need in this rare genetic disorder and positions Redemplo as a promising new targeted treatment option, potentially improving patient access across the EU.

• The European Commission has granted marketing authorization for Arrowhead's Redemplo (plozasiran) for familial chylomicronemia syndrome (FCS) in adults. This approval, following US authorization, is significant as it does not require genetic confirmation of FCS, potentially broadening access for clinically diagnosed patients across the EU and supporting market uptake for this rare genetic disorder.
• The EU approval was supported by robust Phase III PALISADE study data, which demonstrated a median 80% reduction in triglyceride levels at month 10 with Redemplo 25mg. Furthermore, a pooled analysis across all doses showed an 83% reduction in the incidence rate of acute pancreatitis, highlighting Redemplo's potential to significantly improve FCS management.
• Redemplo's mechanism as an apolipoprotein C III (apoC-III) inhibitor represents an important advance over conventional triglyceride-lowering treatments, signaling a shift towards targeted therapies. Its less-frequent administration compared to competing apoC-III inhibitors like Tryngolza and Waylivra may offer a competitive advantage and support its favorable positioning in the expanding FCS treatment market.

The Persistent Challenges in Treating Familial Chylomicronemia Syndrome

Familial chylomicronemia syndrome remains one of the more diagnostically and therapeutically complex disorders in lipidology, compounded by the fact that the overwhelming majority of adults presenting with chylomicronemia carry multifactorial chylomicronemia syndrome (MCS) rather than true FCS. Accurate differentiation requires a multimodal assessment encompassing medical history, physical examination, laboratory testing — including plasma apolipoprotein B and the triglyceride-to-total cholesterol ratio — validated clinical scoring systems, and selective genetic testing when FCS is clinically suspected.

• Diagnostic inconsistency and definitional gaps: There remains an unmet need to harmonize definitions of hypertriglyceridemia (HTG) across clinical and research settings, which continues to impede consistent identification and appropriate management of patients with severe HTG and FCS.

• Limitations of conventional therapy: Traditional management — comprising strict dietary fat restriction, total alcohol avoidance, secondary factor modification, and triglyceride-lowering agents such as fibrates and omega-3 fatty acids — provides incomplete disease control and does not adequately address the underlying pathophysiology of FCS.

• Residual cardiometabolic risk: Beyond the well-established risk of acute pancreatitis, patients with FCS may also be subject to atherosclerotic cardiovascular disease (ASCVD), broadening the clinical risk profile that treatment strategies must address.

• Emerging RNA-based therapies and their nuanced benefit-risk profile: Agents targeting apolipoprotein C-III — including volanesorsen, olezarsen, and plozasiran — offer transformative potential for FCS and select refractory patients with other chylomicronemia subtypes. A recent trial confirmed clinically meaningful benefit in patients with triglycerides >500 mg/dL (5.6 mmol/L), demonstrating substantial triglyceride reduction and a lower incidence of acute pancreatitis; however, these benefits were accompanied by an increase in low-density lipoprotein-cholesterol, a reduction in remnant cholesterol, and no change in apolipoprotein B — a lipid profile shift that warrants careful interpretation in long-term cardiovascular risk assessment.

Redemplo's Phase III PALISADE Data: Efficacy and Safety Outcomes

Two apolipoprotein C-III (apoC-III) inhibitors have been evaluated in pivotal clinical trials for familial chylomicronemia syndrome (FCS): olezarsen, studied in the Balance trial, and plozasiran, studied in the PALISADE trial. Both agents target the apoC-III pathway to reduce triglyceride levels, and both have demonstrated significant reductions in plasma triglycerides and acute pancreatitis (AP) incidence in patients with FCS. Plozasiran has since received US Food and Drug Administration approval for FCS management and offers a less frequent dosing schedule of four administrations per year, compared to twelve per year for olezarsen. However, plozasiran carries a higher annual cost of approximately $72,000 versus $40,000 for olezarsen, a disparity that may constrain real-world access despite its adherence advantage. A recent trial also confirmed benefit in patients with triglycerides exceeding 500 mg/dL (5.6 mmol/L), reporting an increase in low-density lipoprotein-cholesterol, a reduction in remnant cholesterol, and no change in apolipoprotein B.

An anchored matching-adjusted indirect comparison between the Balance and PALISADE trials found no statistically significant differences in 52-week efficacy or safety between olezarsen and plozasiran. The mean difference in triglyceride reduction favored olezarsen by −15.5% (95% CI: −76.2, 45.2), and the mean difference in apoC-III reduction was −8.4% (95% CI: −69.7, 53.0), neither reaching statistical significance. On the safety side, relative risks for AP, treatment-emergent adverse events, and serious adverse events were 0.70 (95% CI: 0.07, 6.66), 0.81 (95% CI: 0.58, 1.13), and 0.50 (95% CI: 0.10, 2.58), respectively — all with confidence intervals crossing unity, indicating no statistically significant between-agent differences.

Despite these encouraging findings, important evidence gaps remain. Long-term outcomes data for plozasiran use in FCS patients are currently limited, and the broad confidence intervals in the indirect comparison reflect the inherent constraints of cross-trial analyses in a rare disease population. Broader efforts are also underway to harmonize definitions of hypertriglyceridemia and improve care pathways for individuals with severe hypertriglyceridemia and FCS, with emerging international registries beginning to generate real-world data linking hypertriglyceridemia to other cardiometabolic disorders.

Redemplo's Position in the Evolving ApoC-III Inhibitor Landscape

Plozasiran (Redemplo) shares its therapeutic rationale — hepatic ApoC-III suppression to reduce triglyceride levels — with olezarsen (Tryngolza), an antisense oligonucleotide (ASO) that similarly inhibits ApoC-III mRNA expression. Both agents have been evaluated in placebo-controlled Phase 3 trials for familial chylomicronemia syndrome (FCS), with GalNAc conjugation used in both modalities to enhance hepatocyte-selective delivery, enabling lower systemic exposure and less frequent dosing. While olezarsen received FDA approval in December 2024, plozasiran followed in November 2025, establishing two approved ApoC-III–targeting agents within the same indication.